Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2010
08/03/2010CA2430091C An antibiotic/analgesic formulation and a method of making this formulation
08/03/2010CA2409828C Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/03/2010CA2407335C Process and device for producing liquid dosage formulations
08/03/2010CA2402199C Amidino compounds useful as nitric oxide synthase inhibitors
08/03/2010CA2396524C System for stabilizing lacrimal fluid layer
08/03/2010CA2386325C Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
08/03/2010CA2382223C Fat or oil composition
08/03/2010CA2361949C Heparin, or heparin conjugate, islets of langerhans
08/03/2010CA2306343C Novel aryloxy-alkyl-dialkylamines
08/03/2010CA2294101C A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
08/03/2010CA2262423C Human monoclonal antibodies specific for hepatitis c virus (hcv) e2 antigen
08/03/2010CA2247247C Troponin subunits and fragments useful as angiogenesis inhibitors
08/03/2010CA2230748C Rapamycin formulations for oral administration
08/03/2010CA2227706C Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
08/03/2010CA2224777C New immunoregulatory protein lst-1
08/03/2010CA2204748C Use of dioxomorpholines for combating endoparasites, new dioxomorpholines and processes for their preparation
08/03/2010CA2188813C Angiostatin protein, nucleic acids encoding the same and methods of detection
07/2010
07/30/2010CA2691905A1 Reservoir eluting stent
07/29/2010WO2010085820A2 Tricyclic compounds as antagonists of prostaglandin d2 receptors
07/29/2010WO2010085811A2 Use of pterosin compounds for treating diabetes and obesity
07/29/2010WO2010085799A2 Compositions and method for the treatment of parkinson's disease
07/29/2010WO2010085797A2 Arginase inhibitors and methods of use
07/29/2010WO2010085788A1 Methods of treating muscular dystrophies
07/29/2010WO2010085753A1 Rosacea treatments and kits for performing them
07/29/2010WO2010085749A2 Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability
07/29/2010WO2010085724A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
07/29/2010WO2010085717A1 Pharmaceutical composition comprising racemic aminopterin
07/29/2010WO2010085699A2 Mammalian piggybac transposon and methods of use
07/29/2010WO2010085697A1 Improved vaccines for human papilloma virus and methods for using the same
07/29/2010WO2010085684A1 Compositions and methods for inhibition of the jak pathway
07/29/2010WO2010085661A1 Modified peptides and their use
07/29/2010WO2010085654A1 Hedgehog pathway inhibitors
07/29/2010WO2010085643A1 Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
07/29/2010WO2010085641A1 Process for preparing particles of opioids and compositions produced thereby
07/29/2010WO2010085609A2 Controlled release systems from polymer blends
07/29/2010WO2010085607A1 Continuous double emulsion process for making microparticles
07/29/2010WO2010085597A1 Macrocyclic compounds and their use as kinase inhibitors
07/29/2010WO2010085589A2 Desensitizing drug product
07/29/2010WO2010085584A1 Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
07/29/2010WO2010085582A1 Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
07/29/2010WO2010085581A1 Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
07/29/2010WO2010085572A1 Method of treating dry eye disease with azithromycin
07/29/2010WO2010085570A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
07/29/2010WO2010085568A1 Methods of diagnosing and treating severe dry eye syndrome
07/29/2010WO2010085535A1 Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health
07/29/2010WO2010085530A1 A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
07/29/2010WO2010085528A1 Bridged and fused antidiabetic compounds
07/29/2010WO2010085525A1 Bridged and fused heterocyclic antidiabetic compounds
07/29/2010WO2010085522A1 Pentafluorosulpholane-containing antidiabetic compounds
07/29/2010WO2010085511A1 Method for treating prostate cancer
07/29/2010WO2010085462A1 Method for treating triple negative breast cancer
07/29/2010WO2010085385A1 Methods for suppressing tip dc trafficking or accumulation and preventing hypercytokinemia
07/29/2010WO2010085377A2 Hydroxamic acid derivatives
07/29/2010WO2010085363A1 Estrus synchronization preparations and effective cidr-less protocols
07/29/2010WO2010085354A1 Delayed release rasagiline formulation
07/29/2010WO2010085352A2 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
07/29/2010WO2010085317A1 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
07/29/2010WO2010085262A1 In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
07/29/2010WO2010085246A1 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors
07/29/2010WO2010085158A1 Improved animal treatment
07/29/2010WO2010085149A1 Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed
07/29/2010WO2010085145A1 Method for the prophylaxis or treatment of flushing
07/29/2010WO2010085128A2 Processes for preparing hiv reverse transcriptase inhibitors
07/29/2010WO2010085047A2 Solid pharmaceutical composition comprising amlodipine and losartan
07/29/2010WO2010085027A1 Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
07/29/2010WO2010085014A1 Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
07/29/2010WO2010084979A1 Benzodiazepin-2-on derivatives
07/29/2010WO2010084944A1 NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND
07/29/2010WO2010084798A1 Tricyclic compound
07/29/2010WO2010084797A1 Hetero atom-containing compound
07/29/2010WO2010084767A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
07/29/2010WO2010084668A1 Diagnostic method for nephrotic syndrome, prophylactic or therapeutic agent for nephrotic syndrome, and method for screening the prophylactic or therapeutic agent
07/29/2010WO2010084661A1 Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound
07/29/2010WO2010084637A1 Tablet for oral administration having excellent disintegrability and dissolvability
07/29/2010WO2010084512A1 Novel oxime derivatives
07/29/2010WO2010084500A1 New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
07/29/2010WO2010084458A1 A novel dermaceutical cream made using sodium fusidate, antifungals and steroids
07/29/2010WO2010084457A1 A novel dermaceutical cream made using sodium fusidate and steroids
07/29/2010WO2010084438A1 Amino-heterocyclic compounds used as pde9 inhibitors
07/29/2010WO2010084428A1 Substituted pyrazinone amides
07/29/2010WO2010084425A1 New adenosine receptor ligands and uses thereof
07/29/2010WO2010084384A1 Combinations of an antiplatelet agent and an antioxidant for the treatment of vascular disorders
07/29/2010WO2010084371A1 Novel circular interfering rna molecules
07/29/2010WO2010084356A1 Treatment of neurotrophic factor mediated disorders
07/29/2010WO2010084275A1 Simplified method for partial genetic and epigenetic reprogramming of cells
07/29/2010WO2010084201A1 Novel derivative of erythromycin for the treatment and diagnosis of prion disease
07/29/2010WO2010084199A1 Drug delivery system for use in the treatment of vascular and vessel-related pathologies
07/29/2010WO2010084188A1 Delayed-release glucocorticoid treatment of asthma
07/29/2010WO2010084186A1 Salts and polymorphs of a kinesin inhibitor compound
07/29/2010WO2010084185A1 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use
07/29/2010WO2010084184A1 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use
07/29/2010WO2010084182A1 Methods for making valerenic acid derivatives and their use
07/29/2010WO2010084160A1 Phenylcyclopropylamine derivatives and their medical use
07/29/2010WO2010084152A1 Novel bicyclic antibiotics
07/29/2010WO2010084134A1 Phd2 inhibition for blood vessel normalization, and uses thereof
07/29/2010WO2010084121A1 Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use
07/29/2010WO2010084120A1 N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands
07/29/2010WO2010084111A2 Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
07/29/2010WO2010084097A1 Spiroindolinone derivative prodrugs
07/29/2010WO2010084066A1 Pharmaceutical composition comprising aleglitazar